Unlocking gene control mechanisms to develop small molecule therapies


Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes.


Year Invested: 2016
Location: Cambridge, MA
Visit: www.fulcrumtx.com

Recent News

May 10, 2017
Fulcrum Therapeutics Announces Additional Series A Financing from GV

May 3, 2017
Fulcrum Therapeutics Expands Leadership Team with Appointment of Owen Wallace, Ph.D., as Chief Scientific Officer and Amit Hasija as Chief Business Officer

February 7, 2017
Fulcrum Therapeutics Strengthens its Board of Directors with the Addition of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D.

Read More News

Associated Team Members

Mark Levin
Partner

Philip Reilly, M.D., J.D.
Venture Partner